logo
Nightclub worker diagnosed with brain tumour reveals key early sign

Nightclub worker diagnosed with brain tumour reveals key early sign

Yahooa day ago

A Birmingham nightclub worker was diagnosed with a brain tumour after getting lost in a place he knew "like the back of his hand".
Tom Weatherstone, from Sheldon, had visited Perranporth in Cornwall all his life but couldn't find his way back from the beach in summer 2022.
After he was diagnosed, he said his confusion may have been the first sign something was wrong.
READ MORE: Dad who built £180k back garden bungalow for ill father has days to tear it down
He also started having headaches, sickness and blurry pixelated vision in his right eye but his family believed they were linked to his job and lifestyle.
He was diagnosed less than a year later after he was sent for blood tests and a CT scan by a doctor who spotted his hand tremors during a routine and unrelated private appointment in March 2023.
The now-23-year-old was previously told he had a vitamin deficiency following a telephone consultation with his GP and was prescribed vitamin B12, D and folic acid.
He was told he needed surgery to treat it, which could result in him losing his sight, his memory, his mobility or even his speech.
Tom said: 'Retrospectively, the first sign came earlier, during a family holiday in the summer of 2022.
'One day, I walked back from the beach and got lost in a place I had known my whole life like the back of my hand.
"At the time, it seemed odd, but we didn't think much of it. Looking back, it was the beginning of something none of us could have imagined.'
READ MORE: City station attacker who 'bit and clawed' police dies at bail hostel
Tom's oldest sister, Josie, 27, said: 'When Tom started having headaches, throwing up, vision problems, and noticing a tremor in his hand, we put it down to his lifestyle and assumed his job in a nightclub, the noise and bright lights were the cause.
'After Tom was diagnosed with a mineral deficiency, none of us thought it was a symptom of a brain tumour.'
Tom continued: 'I had more bloods taken, another CT scan, and a sight test done at Heartlands Hospital in March 2023.
'By early the next morning, they confirmed again there was something there.
'I was transferred that same day to the Queen Elizabeth Hospital in Birmingham. I remember the anxiety building.
'I was scared. I just wanted to know what was in my head that was causing so much alarm.'
At the QE, Tom was diagnosed with an astrocytoma, a tumour which develops from star-shaped glial cells, and had urgent surgery to fit a shunt to relieve pressure on his brain and a biopsy.
He said: 'Doctors said the risks of surgery were loss of sight, mobility, memory or even speech loss.
'I was on my own, no family, and the doctor just said: 'It's a tumour'. I didn't know what to say.
'I rang my family straight away, I was in shock, devastated.
'I'd gone to the doctor for a routine check and now I was in hospital with a brain tumour.'
Tom had a second operation on May 22 2023 to 'debulk' the tumour, which resulted in the partial loss of peripheral vision in his right eye.
READ MORE: Hero police officer saves woman from dog attack which nearly killed her
Five days later, Tom returned home to recover, but at his follow-up appointment, he was given the devastating news that the tumour had progressed from grade 2 to grade 4.
He said: 'When I heard it was grade 4, I put on a brave face, but inside I was crushed.
'I stayed positive, I had to, but it wasn't easy.'
Tom underwent six weeks of radiotherapy, followed by a year of chemotherapy.
In December 2024, an MRI scan revealed a second astrocytoma, inoperable due to its sensitive location, but stable.
A third tumour is not responding to treatment. He now undergoes MRI scans every three months.
Now Josie and Tom's younger sister Gemma, 19, are taking on the 88 Squats a Day in July challenge to raise money for Brain Tumour Research in support of Tom and others affected.
They can be backed on their JustGiving page here.
Josie said: 'If we'd known Tom's symptoms were those of a brain tumour, we'd have taken him straight to hospital.
'I'm taking on the 88 Squats a Day Challenge for Tom because no-one should have to go through what he has.
'Watching someone you love face a brain tumour is heartbreaking.
'If raising awareness and money helps even one family get an earlier diagnosis or better treatment, every squat is worth it.'
Get the latest BirminghamLive news direct to your inbox
Katrina Jones, head of community and digital fundraising at Brain Tumour Research, said: 'We're incredibly grateful to Josie for taking on the 88 Squats Challenge in support of Tom.
'Her determination and strength are truly inspiring.
'Brain tumours are the biggest cancer killer of children and adults under 40 in the UK, yet research into them remains severely underfunded.
'Supporters like Josie play a vital role in helping us fund the research needed to improve outcomes and ultimately find a cure."
Brain Tumour Research funds sustainable research at dedicated centres in the UK.
It also campaigns for the Government and larger cancer charities to invest more in research into brain tumours to speed up new treatments for patients and, ultimately, find a cure.
The charity is the driving force behind the call for a national annual spend of £35 million to improve survival rates and patient outcomes in line with other cancers such as breast cancer and leukaemia.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tool Predicts if Seniors with Cancer Can Stay Home Post Op
Tool Predicts if Seniors with Cancer Can Stay Home Post Op

Medscape

time24 minutes ago

  • Medscape

Tool Predicts if Seniors with Cancer Can Stay Home Post Op

TOPLINE: A novel predictive model named STAYHOME effectively estimated the risk of losing the ability to live at home among older adults after cancer surgery, demonstrating good calibration with minimal deviation from observed risks. The model predicted a 2.4% and 3.4% risk for admission to a nursing home at 6 months and 12 months, respectively. METHODOLOGY: Older adults prioritize long-term functional independence, and the ability to return and stay at home after cancer surgery remains a key concern. However, current prognostic tools focus on short-term outcomes, lacking individualized long-term risk estimates. To estimate the risk of losing the ability to live at home post-surgery, researchers developed and internally validated a risk prediction model, named STAYHOME, among 97,353 community-dwelling older adults (median age, 76 years) who underwent cancer surgery between 2007 and 2019. The predictive model included preoperative variables such as age, sex, rural residence, previous cancer diagnosis, surgery type, frailty, receipt of home care support, receipt of neoadjuvant therapy, cancer site, and cancer stage. The primary outcome was the inability to stay at home after cancer surgery, defined as the time to admission to a nursing home, and was measured at 6 months and 12 months. TAKEAWAY: Overall, 2658 patients (2.7%) at 6 months and 3746 (3.8%) at 12 months were admitted to a nursing home post-surgery. The mean predicted risk of not staying home was 2.4% at 6 months and 3.4% at 12 months. The STAYHOME tool demonstrated a strong predictive capability, with areas under the curve of 0.76 and 0.75 for 6- and 12-month predictions, respectively. The tool also demonstrated minimal deviation from the observed risk for 6-month (0.33 percentage point on average; calibration slope, 1.27) and 12-month (0.46 percentage point on average; calibration slope, 1.17) predictions. The model's calibration was excellent for most predictors at 6 months and 12 months, with a deviation of < 0.8 percentage points from the observed probability; only age older than 85 years (1.13%), preoperative frailty (1.16%), and receipt of preoperative home care support (1.25%) exceeded the deviation of 1 percentage point at 12 months. Across risk deciles, deviations between predicted and observed probabilities were 0.1%-1.5% at 6 months and 0.1%-1.9% at 12 months, reflecting good calibration. The deviation for the slight overestimation at or above the seventh decile remained under 2% for both timepoints. IN PRACTICE: 'The STAYHOME tool demonstrated good discrimination and was well calibrated. Thus, it may be a useful tool to identify a specific group of individuals at risk of not remaining home,' the authors wrote. '[The tool] used information readily available to patients, care partners, and healthcare professionals and may be implemented to provide them with individualized risk estimates and improve surgical oncology care delivery and experience for older adults,' they concluded. SOURCE: This study, led by Julie Hallet, MD, Odette Cancer Centre, Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, was published online in JAMA Surgery. LIMITATIONS: The STAYHOME tool showed slightly reduced discrimination for predictor levels of preoperative frailty, preoperative home care use, receipt of neoadjuvant therapy, and having stage IV disease. The model was also less well calibrated at the extremes of the risk distribution, with a slight overestimation in higher-risk categories. DISCLOSURES: This study was funded by operating grants from the Canadian Institutes for Health Research, Ontario Cancer Research Institute, and ICES. One author reported receiving speaker fees from Ipsen, outside the submitted work. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Portable devices 'life-changing' for patients
Portable devices 'life-changing' for patients

Yahoo

time24 minutes ago

  • Yahoo

Portable devices 'life-changing' for patients

A cancer charity has donated equipment worth almost £10,000 to help palliative care patients enjoy "everyday family life". Easington's East End Cancer Relief Charity (EECR) has provided eight "life-changing" ambulatory syringe drivers to Castle Hill Hospital in Cottingham, East Yorkshire. The small and portable devices are used to continually administer a patient's medication over a set period, the charity said. Locally, the devices have recently been used by a woman attending her sister's wedding and by a teenager attending a music festival, a spokesperson added. The charity, which is already planning further fundraising events, raised a total of £9,600 through activities, including a bike ride, craft fairs, raffles and a country and western night. Charity trustee Andrea Robinson said: "We are immensely proud to be able to provide support in this way and it was fantastic to hear first-hand from the nursing staff the difference the syringe drivers make to patients' lives. "I would like to take this opportunity to say a special thank you to everyone who has helped at our events and have donated either money or goods to contribute to the funds raised," she added. EECR was originally set up in the late 1970s and over the years has raised more than £190,000. It became a registered charity in May 2023. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Children's cancer wig charity plans expansion Cancer patients 'priced out' of holidays, charity warns Double trek made cancer survivor 'feel alive' Hull University Teaching Hospitals NHS Trust

Engineered E. Coli Transforms Waste Plastic Into Common Painkiller
Engineered E. Coli Transforms Waste Plastic Into Common Painkiller

Yahoo

time34 minutes ago

  • Yahoo

Engineered E. Coli Transforms Waste Plastic Into Common Painkiller

New research has made encouraging progress in tackling not one but two of the biggest problems facing our planet right now: plastic pollution and the use of fossil fuels as part of drug manufacturing processes. Scientists from the University of Edinburgh in the UK have used Escherichia coli bacteria to convert molecules from the widely used polyethylene terephthalate (PET) plastic into the painkiller acetaminophen (also known as paracetamol). Like a lot of drugs today, acetaminophen is mostly made out of fossil fuels. Switching those ingredients for waste products – like plastic – could offer an ingenious way of addressing two major environmental problems in one. It's going to take a while to scale this up and prove it can be effective at an industrially and commercially viable level, so we shouldn't get too far ahead of ourselves, but there's a lot of potential in the new technology. "This work demonstrates that PET plastic isn't just waste or a material destined to become more plastic – it can be transformed by microorganisms into valuable new products, including those with potential for treating disease," says biotechnologist Stephen Wallace from the University of Edinburgh. The process starts by chemically degrading PET bottles. The resulting molecules are then fed to engineered E. coli, which use phosphate as a catalyst to convert the molecules into an organic compound containing nitrogen. Finally, these compounds are turned into the active ingredient of acetaminophen. Among the numerous advantages of the process are that it can be completed in 24 hours in a compact laboratory setup, and that it works at room temperature, so there's no need for excessive heating or cooling. What's more, the team has managed to get it working at an impressively efficient 92-percent yield. The reaction makes use of a well-established chemical reaction called the Lossen rearrangement, named after German chemist Wilhelm Lossen, who discovered it in 1872. Here, the reaction is made biocompatible so it can work in cells and living bacteria. Related: This was all done using PET bottles, but the plastic is also used extensively in food packaging, furniture, and manufacturing. This type of plastic is estimated to account for more than 350 million tons of waste per year, adding to the plastic pollution burden. The same approach might also work for other types of bacteria and other types of plastic, according to the researchers, so there's potential here for more environmentally friendly recycling and drug production options. It's a powerful example of how both natural and synthetic chemistry can be combined to find solutions to problems and drive innovation, and it may ultimately mean that E. coli plays a part in the production of our pain relief in the future. "Nature has evolved an exquisite yet limited set of chemical reactions that underpin the function of all living organisms," write the researchers. "By contrast, the field of synthetic organic chemistry can access reactivity not observed in nature, and integration of these abiotic reactions within living systems offers an elegant solution to the sustainable synthesis of many industrial chemicals from renewable feedstocks." The research has been published in Nature Chemistry. The Human Epoch Doesn't Officially Exist. But We Know When It Began. Flesh-Eating Fly Invasion Could Cause Devastation Across America Ocean Acidity Has Reached Critical Levels, And We're All Under Threat

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store